| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Prepaid expenses and other current assets | 12,340 | 8,935 | 13,605 | 15,886 |
| Total current assets | 307,675 | 300,363 | 347,718 | 568,364 |
| Long-term investments | 102,825 | 153,406 | 140,395 | - |
| Property and equipment, net | 894 | 733 | 681 | 821 |
| Operating lease right-of-use assets | 10,295 | 10,539 | 10,778 | 11,244 |
| Deferred tax asset | 25,022 | 25,366 | 26,391 | 27,055 |
| Other non-current assets | 1,589 | 1,720 | 1,882 | 2,231 |
| Total assets | 448,300 | 492,127 | 527,845 | 609,715 |
| Accrued expenses and other current liabilities | 20,439 | 24,002 | 19,070 | 18,963 |
| Total current liabilities | 29,122 | 29,694 | 24,202 | 26,406 |
| Long term debt | 109,816 | 109,545 | 109,252 | 75,700 |
| Operating lease liabilities | 7,759 | 7,940 | 8,115 | 8,443 |
| Other non-current liabilities | 29 | 29 | 29 | 29 |
| Total liabilities | 146,726 | 147,208 | 141,598 | 110,578 |
| Ordinary shares 0.002 nominal value222,480,776shares authorized, 134,421,149 issued and outstanding at september30, 2025 184,469,623 shares authorized, 132,631,587 issued and outstanding at december31, 2024 | 364 | 363 | 362 | 357 |
| Additional paid-in capital | 1,418,681 | 1,408,145 | 1,398,647 | 1,374,058 |
| Accumulated other comprehensive income | 2,600 | 1,591 | 2,075 | 2,095 |
| Accumulated deficit | -1,120,071 | -1,065,180 | -1,014,837 | -877,373 |
| Total shareholders equity | 301,574 | 344,919 | 386,247 | 499,137 |
| Total liabilities and shareholders' equity | 448,300 | 492,127 | 527,845 | 609,715 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)